These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1667252)

  • 21. In vitro antibacterial activity of a new quinolone, NM394.
    Ozaki M; Matsuda M; Tomii Y; Kimura K; Kazuno K; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2490-5. PubMed ID: 1667251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
    Padeĭskaia EN; Mnatsakanian VE
    Antibiot Khimioter; 1991 Jul; 36(7):25-8. PubMed ID: 1953184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.
    Asahara M; Tsuji A; Goto S; Masuda K; Kiuchi A
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1144-52. PubMed ID: 2679369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 26. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.
    Tougou K; Nakamura A; Watanabe S; Okuyama Y; Morino A
    Drug Metab Dispos; 1998 Apr; 26(4):355-9. PubMed ID: 9531524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
    Segawa J; Kitano M; Kazuno K; Matsuoka M; Shirahase I; Ozaki M; Matsuda M; Tomii Y; Kise M
    J Med Chem; 1992 Dec; 35(25):4727-38. PubMed ID: 1335082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
    Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
    J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
    Yoshizumi S; Domon H; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Apr; 42(4):785-8. PubMed ID: 9559783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 33. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
    Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
    J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
    Chodosh S
    Am J Med; 1991 Dec; 91(6A):93S-100S. PubMed ID: 1662900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
    Fukuoka Y; Ikeda Y; Yamashiro Y; Takahata M; Todo Y; Narita H
    Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.